CSCO Yu Zhentao: Research and prospect of new complementary treatment of esophageal cancer.

The new auxiliary treatment of esophageal cancer has been carried out in our country for many years, the earliest new auxiliary treatment research is preoperative radiotherapy treatment, drinking blood development so far, what development and changes have the new auxiliary treatment of esophageal cancer? China's new auxiliary treatment for esophageal cancer in the world has not healed the low and middle levels? September 19 "23rd National Conference on Clinical Oncology and 2020 CSCO Academic Annual Meeting", the Academy of Medical Sciences Cancer Hospital Professor Yu Zhentao, for you to answer.
The exploration of new complementary treatment of esophageal cancer in the international field In 2008, a 9781 study by Duke University in the United States established the position of triple therapy in preoperative treatment of esophageal cancer, through which a triple therapy can achieve a better five-year survival than simple surgery.
later Cross study showed that the group of patients who had simultaneous preoperative chemotherapy plus surgery had significantly higher five-year survival than those who had simple surgery.
9901 study in France, which also showed that the pfs group had a more obvious benefit, but there was a tendency to benefit from it, compared with preoperative simultaneous chemotherapy and surgery in patients with early esophageal cancer.
based on this study, European scholars believe that early stage patients with esophageal cancer do not need to do preoperative simultaneous chemotherapy.
Japanese experts published 9907 studies in 12 years, making preoperative complementary chemotherapy a standard treatment in Japan.
under such a scheme, we can see clear advantages over pure surgery.
But in 16 years, 30 centres in France also reviewed T2N0M0 patients and found that selenium-assisted therapy may not be a benefit to patients, so surgical treatment is recommended for such early patients.
and the United States has published two studies, one in which patients who reach PCr in new complementary treatments can benefit from the new complementary treatments.
Japan and the United Kingdom have also recently published a number of single-center studies, after local esophageal cancer removal treatment, cCR patients receive surgery more than non-surgical benefits.
, how do I screen sensitive people? How can I increase the depth mitigation rate? will be the main issue to consider in the future! The history and status of new auxiliary treatment of esophageal cancer in China has been carried out for many years, the earliest relevant research is preoperative radiotherapy, 92 Chinese Academy of Medical Sciences Cancer Hospital published a retrospective analysis of more than 1000 cases, the results show that preoperative radiotherapy increased R0 excision rate, the upper part of esophageal cancer patients from preoperative radiotherapy significantly benefited.
2001, the Oncology Hospital of the Chinese Academy of Medical Sciences published a forward-looking single-center study of 418 patients, but the results showed that there was no significant difference in survival rates among patients undergoing postoperative radiotherapy compared to patients undergoing direct surgery.
a forward-looking study in Hong Kong compared preoperative chemotherapy with pure surgery, concluding that preoperative chemotherapy was safe and could improve the rate of cured excision.
Shanxi Cancer Hospital published a forward-looking clinical study of 50 patients in 2001 and found that preoperative chemotherapy reduced postoperative recurrence and metastasis rates, while improving patient survival for 5 years.
in 2015, Xi'an ObsteutsionAl Hospital published a comparison of PCF (yew alcohol, cisplatin, FU) three drug programs of the new auxiliary chemotherapy and peri-surgical chemotherapy on the efficacy of removable esophageal cancer.
results showed that perioperative treatment improved patients' disease-free survival and total survival for 5 years compared to the preoperative three-drug chemotherapy program.
The Oncology Hospital of the Chinese Academy of Medical Sciences published a retrospective analysis in 2017 to verify the safety of the yew alcohol combined platinum bi-weekly program, which found that bi-weekly drug use can improve patient efficacy and reduce adverse reactions in patients.
It can be said that the new auxiliary chemotherapy is the most important area of work in the field of esophageal cancer in China in 20 years, but most of the research focuses on the improvement and optimization of the purple shirt-based chemotherapy program, that is, most of the research programs and cross-research programs are the same, the content is slightly repeated.
Although we have lacked data levels in the field of new assisted chemotherapy for esophageal cancer over the years, we have drawn on the results of western cross studies, the results of 9901 studies, and we have done 5010 studies ourselves, believing that in the future we will have more research centers and more clinical data to help us do more work in the field of esophageal cancer.
years, immunotherapy has also reached a new milestone in the study of esophageal squamous cancer.
whether it is the treatment of advanced esophageal cancer or preoperative ancillary treatment, in many research centers are in full swing to carry out related research.
For targeted treatment, and lung cancer, esophageal cancer is actually the corresponding target, these targets can produce the corresponding drugs to have a far-reaching impact on the treatment of esophageal cancer, which is one of the things we need to continue to pay attention to.
At present, compared with the international field, domestic esophageal cancer research is slightly backward, I believe that our future esophageal cancer new auxiliary treatment research will have a big breakthrough, can open our door to accurate treatment of esophageal cancer.
Medical Forum Network Source: Medical Forum.com Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.